New Guidance on Resmetirom and Semaglutide for MASHNew Guidance on Resmetirom and Semaglutide for MASH
(MedPage Today) — At the American Association for the Study of Liver Diseases (AASLD) annual meeting, a session highlighted new guidance on using resmetirom (Rezdiffra) and semaglutide (Ozempic, Wegovy) for metabolic dysfunction-associated steatohepatitis… (MedPage Today) — At the American Association for the Study of Liver Diseases (AASLD) annual meeting, a session highlighted new guidance Read More
GLP-1s Tied to Big Survival Advantage in Colon Cancer PatientsGLP-1s Tied to Big Survival Advantage in Colon Cancer Patients
(MedPage Today) — Patients with colon cancer and a history of treatment with GLP-1 receptor agonists for obesity had a 5-year mortality rate that was less than half the rate for patients who didn’t take these drugs, according to a large retrospective… (MedPage Today) — Patients with colon cancer and a history of treatment Read More
Not-So-‘Sneaky’ Cells; Exercise for Breast Cancer; More Uses for AI in CancerNot-So-‘Sneaky’ Cells; Exercise for Breast Cancer; More Uses for AI in Cancer
(MedPage Today) — “Sneaky” senescent cells that promote treatment resistance could prove to be a target for new lung cancer therapies, researchers said. (UCSF Health, Cell Stem Cell)
Competition is heating up in the race to market the first bispecific…
Nixed Hormone Therapy Warning; Making GLP-1s Affordable; What Is ‘Butt Breathing’?Nixed Hormone Therapy Warning; Making GLP-1s Affordable; What Is ‘Butt Breathing’?
(MedPage Today) — The following is a transcript of the podcast episode: Rachael Robertson: Hey everybody, welcome to MedPod Today, the podcast series where MedPage Today reporters share deeper insights into the week’s biggest healthcare stories… (MedPage Today) — The following is a transcript of the podcast episode: Rachael Robertson: Hey everybody, welcome to Read More
GLP-1 and health: Beyond weight loss in the Ozempic eraGLP-1 and health: Beyond weight loss in the Ozempic era
This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people with diabetes and obesity. This week, the White House announced a deal with Eli Lilly and Novo Read More
More Americans use weight loss drugs like Ozempic than live in TexasMore Americans use weight loss drugs like Ozempic than live in Texas
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. The Ig Noble awards just happened, but I’d like to pitch this study — which found that a man’s shouts will scare gulls away from food — for next year’s consideration. Read the rest… Get your Read More
GLP-1 weight-loss medications linked to improved cancer survival in certain patientsGLP-1 weight-loss medications linked to improved cancer survival in certain patients
Colon cancer patients could live longer if they take GLP-1 drugs like Ozempic and Wegovy, a new study suggests. Researchers at UC San Diego studied more than 6,800 patients who were taking one of these popular similar diabetes and weight-loss medications. They found that the patients were much less likely to die within five years Read More
Study shows Ozempic could help dialysis patients qualify for kidney transplantsStudy shows Ozempic could help dialysis patients qualify for kidney transplants
Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians reveals that breakthrough weight loss medications could change that—giving more patients a second chance at life. Obesity is one of the biggest barriers Read More
Ablative Preoperative Single-Fraction Radiation Dose Escalation in Breast CancerAblative Preoperative Single-Fraction Radiation Dose Escalation in Breast Cancer
This nonrandomized clinical trial uses a dose escalation framework to assess the maximum tolerated dose of preoperative ablative stereotactic partial breast irradiation and its associations with oncologic outcomes among patients with breast cancer.
Key HER2-Positive Breast Cancer Therapy Gets Its First BiosimilarKey HER2-Positive Breast Cancer Therapy Gets Its First Biosimilar
(MedPage Today) — The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer.
FDA granted the targeted agent an…